DelveInsight’s, “Alpha-Synuclein Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Alpha-Synuclein Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Alpha-Synuclein Inhibitors: Overview
α-Synuclein is a highly soluble unfolded protein that accumulates in Lewy bodies and Lewy neurites in Parkinson disease and other synucleinopathies. It is abundant in the brain, while smaller amounts are found in the heart, muscle and other tissues. In the brain, alpha-synuclein is found mainly at the tips of neurons in specialized structures called presynaptic terminals
Function - Although the function of alpha-synuclein is not well understood, studies suggest that it plays a role in restricting the mobility of synaptic vesicles, consequently attenuating synaptic vesicle recycling and neurotransmitter release. An alternate view is that alpha-synuclein binds to VAMP2 (a synaptobrevin) and stabilizes SNARE complexes; though recent studies indicate that alpha-synuclein–VAMP2 binding is critical for alpha-synuclein-mediated attenuation of synaptic vesicle recycling, connecting the two seemingly divergent views. It may also help regulate the release of dopamine, a type of neurotransmitter that is critical for controlling the start and stop of voluntary and involuntary movements.
Alpha-Synuclein Inhibitors - Synucleinopathies are a group of disorders characterized by the accumulation of α-Synuclein amyloid inclusions in the brain. Preventing α-Synuclein aggregation is challenging because of the disordered nature of the protein and the stochastic nature of fibrillogenesis, but, at the same time, it is a promising approach for therapeutic intervention in these pathologies.
The companies and academics are working to assess challenges and seek opportunities that could influence Alpha-Synuclein Inhibitors R&D. The therapies under development are focused on novel approaches for Alpha-Synuclein Inhibitors.
This segment of the Alpha-Synuclein Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alpha-Synuclein Inhibitors Emerging Drugs
R-phenserine: Annovis Bio
R -phenserine is a R-enantiomer (positive isomer) of phenserine, being developed by Annovis Bio (formerly QR Pharma), under a licence from Horizon Therapeutics plc (formerly Horizon Pharma), for the treatment of Alzheimer's disease (AD) and dementia in Down syndrome (AD-DS), Parkinson's disease (PD), stroke and traumatic brain injuries. Currently, it is in phase 2 stage of development for the treatment of Mild cognitive impairment.
UCB 0599: UCB Biopharma
UCB0599 is an orally bioavailable, brain barrier penetrant small molecule that prevents the oligomerization of alpha-synuclein. Alpha-synuclein oligomerization and aggregation is implicated in Parkinson’s disease and other degenerative diseases. By inhibiting misfolding and oligomerization of alpha-synuclein, it is believed that the progression of Parkinson’s disease can be slowed or halted. UCB0599 belongs to a series of molecules discovered by Neuropore, which were licensed to UCB in 2014. Currently, it is in phase 2 stage of development for the treatment of Parkinson's disease.
Further product details are provided in the report……..
This segment of the report provides insights about the different Alpha-Synuclein Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 15+ key companies which are developing the Alpha-Synuclein Inhibitors. The companies which have their Alpha-Synuclein Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Annovis Bio.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Alpha-Synuclein Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha-Synuclein Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha-Synuclein Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Alpha-Synuclein Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Alpha-Synuclein Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Alpha-Synuclein Inhibitors Collaboration Deals
Late Stage Products (Pre-registration)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
R-phenserine: Annovis Bio
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ATH 434: Alterity Therapeutics
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
PR 004: Prevail Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Alpha-Synuclein Inhibitors Key Companies
Alpha-Synuclein Inhibitors Key Products
Alpha-Synuclein Inhibitors- Unmet Needs
Alpha-Synuclein Inhibitors- Market Drivers and Barriers
Alpha-Synuclein Inhibitors- Future Perspectives and Conclusion
Alpha-Synuclein Inhibitors Analyst Views
Alpha-Synuclein Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Alpha-Synuclein Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Alpha-Synuclein Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Annovis Bio
• UCB Biopharma
• Alterity Therapeutics
• Denali Therapeutics Inc
• Lundbeck A/S
• AbbVie
• Prevail Therapeutics
• United Neuroscience
• AstraZeneca
• Nitrome Biosciences
• Enterin
• AFFiRiS
• Prothena Corporation
• Roche
• Proclara Biosciences
• Modag
• ProMIS Neurosciences